Date of announcement 2016/12/19
Time of announcement 22:39:32

Date of events 2016/12/19
To which item it meets paragraph 24
Statement
1.Name and nature of the subject matter (if preferred shares,the terms and conditions of issuance shall also be indicated,e.g.dividend yield):
Partnership interests in「CDIB Healthcare Private Equity (Kunshan) Enterprise (Limited Partnership)」(tentative name)
2.Date of occurrence of the event:2016/12/19
3.Volume, unit price, and total monetary amount of the transaction:
Volume and unit price: Not applicable, total monetary amount of the transaction: RMB 1 million
4.Counterpart to the trade and its relationship to the Company(if the trading counterpart is a natural person and furthermore is not an actual related party of the Company, the name of the trading counterpart is not required to be disclosed):
Counterpart：To set up a new company「CDIB Healthcare Private Equity (Kunshan) Enterprise (Limited Partnership )」
Its relationship to the Company：CDIB Venture Capital Corporation, 100% owned subsidiary of CDIB, invests in a new company 「CDIB Healthcare Private Equity (Kunshan) Enterprise (Limited Partnership)」and hold no more than 29.935% of interests of the partnership via 100% owned subsidiary CDIB Venture Capital (Hong Kong) Corporation Limited. CDIB Yida Private Equity (Kunshan) Co. Ltd., 65% owned subsidiary of CDIB, will manage「CDIB Healthcare Private Equity (Kunshan) Enterprise (Limited Partnership )」as a General Partner and as a asset management company.
5.Where the counterpart to the trade is an actual related party,a public announcement shall also be made of the reason for choosing the related party as trading counterpart and the identity of the previous owner (including its relationship with the company and the trading counterpart), price of transfer, and date of acquisition:N/A
6.Where a person who owned the property within the past five years has been an actual related person of the company, a public announcement shall also include the dates and prices of acquisition and disposal by the related person and the person’s relationship to the company at those times:N/A
7.Matters related to the creditor's rights currently being disposed of (including types of collateral of the disposed creditor's rights;if the creditor's rights are creditor's rights toward a related person, the name of the related person and the book amount of the creditor's rights toward such related person currently being disposed of must also be announced):N/A
8.Anticipated profit or loss from the disposal (not applicable in cases of acquisition of securities) (where originally deferred, the status or recognition shall be stated and explained):N/A
9.Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important stipulations:
Payment will be delivered based on the consensus among all investors
10.The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making department:
The manner in which the current transaction was decided, the reference basis for the decision on price：To subscribe the interests of the partnership of 「CDIB Healthcare Private Equity (Kunshan) Enterprise (Limited Partnership )」
The decision-making department：The transaction to be approved by the Board of CDIB Venture Capital (Hong Kong) Corporation Limited.
11.Net worth per share of company underlying securities acquired or disposed of:Not applicable .
12.The discrepancy between the reference price of private placement and the transaction amount per share is 20 percent or more of the transaction amount:Not applicable .
13.Current cumulative volume, amount, and shareholding percentage of holdings of the security being traded (including the current trade) and status of any restriction of rights (e.g.pledges):
(1) Current cumulative volume: Not applicable
(2) Amount: RMB 1 million
(3)Shareholding percentage of holdings of the security being traded: 0.1% of the partnership.
(4) Status of any restriction of rights: None.
14.Current ratio of private placement of securities (including the current trade) to the total assets and shareholder's equity as shown in the most recent financial statement and the operating capital as shown in the most recent financial statement:
(1) to the total assets:41.98 %。
(2) to the shareholder's equity: 73.64 %.
(3) The operating capital: NTD 13,611 thousand.
15.Broker and broker's fee: Not applicable
16.Concrete purpose or use of the acquisition or disposition: For the needs of investment portfolio expansion
17.Do the directors have any objection to the present transaction?:No
18.The trading counterparty is a related party:Yes
19.Approval date by board of directors:2016/12/19
20.Recognition date by supervisors or submission date by audti committee:N/A
21.Has the CPA issued an opinion on the unreasonableness of the price of the current transaction?:N/A
22.Any other matters that need to be specified:
(1) CDIB Yida Private Equity (Kunshan) Co. Ltd., which is 65% owned subsidiary of CDIB, will established CDIB Healthcare Private Equity (Kunshan) Enterprise (Limited Partnership) with tentative fund size of RMB 1,000 million. CDIB will be the key manager and owned no more than 30% of interests of the partnership
(2) CDIB Yida Private Equity (Kunshan) Co. Ltd. will manages CDIB Healthcare Private Equity (Kunshan) Enterprise (Limited Partnership) as a General Partner and as a asset management company. CDIB Yida Private Equity (Kunshan) Co. Ltd. will also invests RMB 1 million in CDIB Healthcare Private Equity (Kunshan) Enterprise (Limited Partnership),
holds 0.1% interests of the partnership.
(3) These transactions will not be processed until approved by the competent authority.